Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Finally A FIBCO, Regeneron Sets Its Sights On Eylea And Beyond

Related Content

Challenging Lucentis: Eylea’s Early Progress Prompts $250 Mil.-$300 Mil. Sales Forecast For 2012

Feb 16 2012

Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis

Nov 21 2011

<em>Eylea</em> Pricing is Eye-Opening: Regeneron Plays to CMS, Payors on Price; Docs with Terms

Nov 14 2011

A Bad Day for Lucentis

Sep 01 2011

Ironwood Pharmaceuticals: Independent for the Long Haul

Sep 01 2010

Bayer/Regeneron: Typically Rich, Extra Regional

Nov 01 2006

Retinal Disease: Much Progress, Some Pain

Feb 24 2012

Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now

Mar 01 2011

Avastin v. Lucentis: An Early Test Case For Medicare ACOs

May 01 2011

Biotech’s Declaration Of Independence And What Pharma Needs To Do About It

Jan 24 2012

Infinity/Purdue: The Challenge of Reprising Roche/Genentech

Jan 01 2009

Related Companies

Regeneron Pharmaceuticals, Inc.

Roche Holding AG

Genentech, Inc.

Sanofi

Bayer AG

Bayer AG

Dendreon Corporation

Amgen, Inc.

Procter & Gamble

Astellas Pharma, Inc.

AstraZeneca PLC

Sanofi

Sanofi

Sanofi

Ironwood Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc.

Acorda Therapeutics, Inc.

Human Genome Sciences, Inc.

Vertex Pharmaceuticals Incorporated

Additional Topics

United States Business Strategies Pricing Strategies Launches Deals Innovation Leadership BioPharmaceutical

More from Business Strategy

More from In Vivo

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window